최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기韓國藥用作物學會誌 = Korean journal of medicinal crop science, v.25 no.5, 2017년, pp.328 - 334
박수빈 (안동대학교 생약자원학과) , 박광훈 (국립산림과학원 산림약용자원연구소) , 송훈민 (안동대학교 생약자원학과) , 박지혜 (안동대학교 생약자원학과) , 신명수 (안동대학교 생약자원학과) , 손호준 (국립산림과학원 산림약용자원연구소) , 엄유리 (국립산림과학원 산림약용자원연구소) , 정진부 (안동대학교 생약자원학과)
Background: In this study, we evaluated the anti-cancer activity and potential molecular mechanism of 70% ethanol extracts of the root of Aralia cordata var. continentalis (Kitagawa) Y. C. Chu (RAc-E70) against human colorectal cancer cells. Methods and Results: RAc-E70 suppressed the proliferation ...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
독활이란 무엇인가? | C.Chu]은 두릅나무과 (Araliaceae)에 속하는 다년생 식물로 땅두릅 또는 풀두릅이라고 하며, 한약명은 독활 또는 독요초로 독활의 뿌리를 사용한다 (Han, 2005). 독활은 혈압강화작용 (Yang et al. | |
독활은 항암활성 이외에 어떤 효능을 가지고 있는가? | Chu]은 두릅나무과 (Araliaceae)에 속하는 다년생 식물로 땅두릅 또는 풀두릅이라고 하며, 한약명은 독활 또는 독요초로 독활의 뿌리를 사용한다 (Han, 2005). 독활은 혈압강화작용 (Yang et al., 2008), 항염증작용 (Park et al., 2005), 항균작용 (Jeong et al., 2006), 항산화 및 항혈소판 작용 (Yang et al., 2008) 등에 효능이 있다고 보고되고 있다. 또한 독활은 다양한 암세포에 대한 항암활성이 있다고 보고되었다 (Park and Kim, 1995). | |
대장암에서의 cyclin D1 유전자의 과대발현과 단백질의 과대발현 비율이 2.5%와 55%로 나타나는 것은 무엇을 의미하는가? | , 2011). 이것은 cyclin D1 단백질의 과대발현은 암세포에서 단백질 분해 기전의 결함에 기인한다는 것을 의미한다 (Gillett et al., 1994; Russell et al. |
Alao JP, Lam EWF, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC and Vigushin DM. (2004). Histone deacetylase inhibitor trichostatin A represses estrogen receptor ${\alpha}$ -dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clinical Cancer Research. 10:8094-8104.
Alao JP, Stavropoulou AV, Lam EW, Coombes RC and Vigushin DM. (2006). Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Molecular Cancer. 5:8-18.
Alao JP. (2007). The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Molecular Cancer. 6:24-39.
Dobos GJ, Tan L, Cohen MH, McIntyre M, Bauer R, Li X and Bensoussan A. (2005). Are national quality standards for traditional Chinese herbal medicine sufficient?: Current governmental regulations for traditional Chinese herbal medicine in certain Western countries and China as the Eastern origin country. Complementary Therapies in Medicine. 13:183-190.
Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D and Peters G. (1994). Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Research. 54:1812-1817.
Gopalakrishnan N, Saravanakumar M, Madankumar P, Thiyagu M and Devaraj H. (2014). Colocalization of ${\beta}$ -catenin with Notch intracellular domain in colon cancer: A possible role of Notch1 signaling in activation of cyclin D1-mediated cell proliferation. Molecular and Cellular Biochemistry. 396:281-293.
Han WS. (2005). Isolation of the antimicrobial compounds from Aralia cordata Thunb. extract. Korean Journal of Medicinal Crop Science. 13:182-185.
Jeong SI, Han WS, Yun YH and Kim KJ. (2006). Continentalic acid from Aralia continentalis shows activity against methicilinresistant Staphylococcus aureus. Phytotherapy Research. 20:511-514.
Jung KW, Won YJ, Oh CM, Kon HJ, Lee DH and Lee KH. (2017). Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2014. Cancer Research and Treatment. 49:292-305.
Kessler RC, Davis RB, Foster DF, Van Rompay MI, Walters EE, Wilkey SA, Kaptchuk TJ and Eisenberg DM. (2001). Long-term trends in the use of complementary and alternative medical therapies in the United States. Annals of Internal Medicine. 135:262-268.
Langenfeld J, Kiyokawa H, Sekula D, Boyle J and Dmitrovsky E. (1997). Posttranslational regulation of cyclin D1 by retinoic acid: A chemoprevention mechanism. Proceedings of the National Academy of Sciences of the United States of America. 94:12070-12074.
Musgrove EA, Caldon CE, Barraclough J, Stone A and Sutherland RL. (2011). Cyclin D as a therapeutic target in cancer. Nature Reviews Cancer. 11:558-572.
Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F and Tetsu O. (2006). A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PloS One. p.1-12. http://journals.plos.org/plosone/article?id10.1371/journal.pone.0000128 (cited by 2017 Oct 20).
Park BK, Lee JH, Cho CK, Shin HK, Eom SK and Yoo HS. (2008). Systemic review of clinical studies about oriental medical treatment of cancer in Korea. Journal of Korean Journal of Oriental Internal Medicine. 29:1061-1074.
Park HJ, Hong MS, Lee JS, Leem KH, Kim CJ, Kim JW and Lim S. (2005). Effects of Aralia continentalis on hyperalgesia with peripheral inflammation. Phytotherapy Research. 19:511-513.
Park SH and Kim J. (1995). Cytotoxic polyacetylenes from Aralia cordata. Archives of Pharmacal Research. 39:681-688.
Qin A, Yu Q, Gao Y, Tan J, Huang H, Qiao Z and Qian W. (2015). Inhibition of STAT3/cyclin D1 pathway promotes chemotherapeutic sensitivity of colorectal caner. Biochemical and Biophysical Research Communications. 457:681-687.
Russell A, Thompson MA, Hendley J, Trute L, Armes J and Germain D. (1999). Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene. 18:1983-1991.
Thoms HC, Dunlop MG and Stark LA. (2007). p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells. Cancer Research. 67:1660-1669.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.